Anti-tumor drug wastewater inactivation device

Abstract

The utility model relates to the technical field of medical treatment, and discloses an anti-tumor drug wastewater inactivation device which comprises a pretreatment assembly, the water inlet end of the high-pressure pump is communicated with a first connecting pipe, the first connecting pipe is connected with the pretreatment assembly, and the water outlet end of the high-pressure pump is communicated with a second connecting pipe; an air pumping assembly; the top ends of the two reactors are communicated with each other, and the bottom end of one reactor is communicated with a connecting pipe V; the cross section of the cooler is of an inverted U-shaped structure, one end of the cooler is communicated with the fifth connecting pipe, and the other end of the cooler is communicated with a sixth connecting pipe; the utility model discloses a gas-liquid separator. According to the antitumor drug wastewater inactivation device provided by the invention, the antitumor drug can be efficiently and effectively degraded, the enrichment of the antitumor drug in a food chain is prevented, the health of aquatic organisms and an ecological system is protected, the potential threat to public health is reduced, and the requirements of environmental protection are met.

Description

Technical Field

[0001] This utility model relates to the field of medical technology, and in particular to a device for inactivating wastewater from antitumor drugs. Background Technology

[0002] With the ever-increasing global cancer incidence rate, the use of anti-tumor drugs is also growing rapidly. Although anti-tumor drugs have made significant contributions to human health, their environmental impact and potential harm should also be taken seriously. Anti-tumor drugs are a double-edged sword. Most anti-tumor drugs are cytotoxic agents and lack selectivity. That is, while killing tumor cells, they can also cause potential teratogenic, carcinogenic, and mutagenic exposure damage to normal cells. Taking platinum-based anti-tumor drugs, which are currently the most widely used, as an example, platinum-based drugs can cause gastrointestinal irritation, toxic side effects on germ cells, hematologic and neurotoxic effects, and certain nephrotoxicity. They can also stimulate the immune system.

[0003] Existing wastewater treatment technologies have significant shortcomings in treating hospital wastewater containing antitumor drugs, small-scale antitumor drug formulations, and wastewater discharged from research and development units. Specific problems are as follows:

[0004] Limitations of traditional biochemical treatment methods: Traditional biochemical treatment relies on the degradation ability of microorganisms on organic pollutants. It utilizes the physiological and biochemical characteristics of microorganisms to enrich, transform, and degrade toxic substances in wastewater to change the wastewater quality and make it meet the discharge standards. However, anti-tumor drugs usually have high biotoxicity and can inhibit or kill the microbial community used for wastewater treatment, thereby undermining the effectiveness of the treatment process. These drugs have complex and stable molecular structures and are difficult to be metabolized or decomposed by conventional microorganisms, which means that they can persist in wastewater treatment facilities and may be discharged into the environment with the treated water.

[0005] The ineffectiveness of high-temperature sterilization and inactivation methods: High temperatures have a significant lethal effect on bacteria. Thermal sterilization mainly utilizes high temperatures to denature or coagulate bacteria, causing enzymes to lose activity and thus killing the bacteria. It is effective for biological inactivation, but it has almost no effect on chemically stable antitumor drugs. These drugs will not undergo sufficient structural changes due to increased temperature to lose their pharmacological activity. In addition, high-temperature treatment may lead to increased energy consumption and operating costs. Moreover, if the temperature is not properly controlled, harmful byproducts may be generated, further increasing environmental risks.

[0006] The shortcomings of existing biological processes in wastewater treatment plants: Most wastewater treatment plants use traditional biological treatment processes based on activated sludge, etc., which were not designed to remove emerging pollutants such as antibiotics and anti-tumor drugs.

[0007] Therefore, existing facilities lack specialized treatment units and technologies for recalcitrant organic matter, especially anti-tumor drugs. This means that even after multi-stage treatment, wastewater may still contain high concentrations of residual drugs, posing a potential threat to the ecosystems in receiving water bodies. Once anti-tumor drugs enter natural water bodies, due to their persistence and bioaccumulation, they may gradually accumulate in the food chain, ultimately affecting the health and stability of the entire ecosystem. For aquatic organisms, even low-dose exposure can cause chronic toxic effects, such as reproductive disorders, growth retardation, and impaired immune systems, thereby affecting population size and biodiversity.

[0008] Therefore, it is necessary to design an inactivation device for antitumor drug wastewater to solve the above problems. Utility Model Content

[0009] The purpose of this invention is to address the shortcomings of existing technologies by proposing an antitumor drug wastewater inactivation device.

[0010] To achieve the above objectives, the present invention adopts the following technical solution:

[0011] The wastewater inactivation device for antitumor drugs includes:

[0012] Pretreatment components are used for the initial treatment of wastewater from antitumor drugs.

[0013] A high-pressure pump, wherein the inlet end of the high-pressure pump is connected to a connecting pipe one, the connecting pipe one being connected to a pretreatment component, and the outlet end of the high-pressure pump is connected to a connecting pipe two.

[0014] An air pumping assembly, comprising an air compressor and an air tank, wherein the output end of the air compressor is connected to the interior of the air tank, and a connecting pipe three is connected to the air tank, the connecting pipe three being connected to a connecting pipe two.

[0015] Two reactors, the top ends of the two reactors are connected, and the bottom end of one of the reactors is connected to a connecting pipe.

[0016] A cooler with an inverted U-shaped cross-section, one end of which is connected to a connecting pipe five, and the other end of which is connected to a connecting pipe six;

[0017] A gas-liquid separator is connected to a connecting pipe. An exhaust pipe is connected to the top of the gas-liquid separator, and a water outlet pipe for discharging oxidizing liquid is connected to the bottom of the gas-liquid separator.

[0018] As a preferred embodiment of the present invention, the pretreatment component includes a pretreatment box, the bottom of the side wall of the pretreatment box is connected to a connecting pipe, a filter is provided in the upper part of the inner side of the pretreatment box, a motor is fixed on the pretreatment box, a stirrer is axially connected to the end of the output shaft of the motor, and the bottom end of the stirrer extends to below the filter.

[0019] As a preferred technical solution of this utility model, it also includes a preheater, the bottom end of which is connected to the second connecting pipe, and the top end of which is connected to the fourth connecting pipe, which is connected to the bottom end of another reactor.

[0020] As a preferred embodiment of this invention, both the preheater and the reactor are fixedly fitted with heating jackets.

[0021] As a preferred embodiment of this utility model, the interior of the side wall of the cooler is hollow, and a circulating water outlet pipe and a circulating water inlet pipe are connected inside the side wall of the cooler, and the circulating water outlet pipe and the circulating water inlet pipe are located at both ends of the cooler respectively.

[0022] As a preferred embodiment of this utility model, the highest point of the cooler and the highest point of the connecting pipe are on the same horizontal line.

[0023] This utility model has the following beneficial effects:

[0024] 1. Highly efficient removal of antitumor drug residues: In this application, oxygen in the air reacts with water to generate hydroxyl radicals, which react rapidly with organic matter in the wastewater, ensuring that antitumor drugs in the wastewater are effectively degraded in a short time, reducing the possibility of them entering natural water bodies. Compared with traditional treatment technologies, this device can prevent the accumulation of antitumor drugs in the food chain, protect the health of aquatic organisms and ecosystems, reduce potential threats to public health, and meet environmental protection requirements.

[0025] 2. Wide range of applications: This application utilizes the principle of hydroxyl radicals reacting with organic matter, which can improve the applicability of the device. This makes the device suitable not only for hospital wastewater treatment, but also for wastewater treatment from small anti-tumor drug formulation plants and research units. Its wide range of applications covers various anti-tumor drug wastewater from low to high concentrations, and it can maintain high efficiency in treatment under different water quality conditions.

[0026] 3. Convenient operation: The operation of the device in this application relies on an automated control system. This automated and continuous design can reduce the labor intensity of the staff, improve the convenience and efficiency of operation, and also improve the overall safety and reliability of the device.

[0027] 4. Simple structure: The entire device in this application has a compact structure and a small footprint, making it suitable for spaces with limited capacity, such as hospitals and small pharmaceutical factories. This improves the versatility of its applications. Furthermore, the integration of all components and electrical modules within a compact frame simplifies the installation and maintenance process, reduces the need for manual intervention, lowers management difficulty and operating costs, and provides room for equipment upgrades. Attached Figure Description

[0028] Figure 1 This is a schematic diagram of the structure of the antitumor drug wastewater inactivation device proposed in this utility model.

[0029] In the diagram: 1 Pretreatment tank, 2 Motor, 3 Agitator, 4 Filter, 5 Connecting pipe 1, 6 High-pressure pump, 7 Connecting pipe 2, 8 Accumulator, 9 Air compressor, 10 Air storage tank, 11 Connecting pipe 3, 12 Preheater, 13 Connecting pipe 4, 14 Reactor, 15 Connecting pipe 5, 16 Cooler, 17 Circulating water outlet pipe, 18 Circulating water inlet pipe, 19 Connecting pipe 6, 20 Gas-liquid separator, 21 Water outlet pipe, 22 Exhaust pipe, 23 Heating jacket. Detailed Implementation

[0030] The technical solutions of the present utility model will be clearly and completely described below with reference to the accompanying drawings of the embodiments of the present utility model. Obviously, the described embodiments are only some embodiments of the present utility model, and not all embodiments.

[0031] Reference Figure 1 Wastewater inactivation device for antitumor drugs, including:

[0032] A pretreatment component is used for the preliminary treatment of antitumor drug wastewater. The pretreatment component includes a pretreatment tank 1, the bottom of which is connected to a connecting pipe 5. A filter 4 is installed in the upper part of the inner side of the pretreatment tank 1. The filter 4 is used to remove larger suspended particles and other solid impurities in the antitumor drug wastewater to prevent interference with the operation of subsequent equipment. A motor 2 is fixed on the pretreatment tank 1. An agitator 3 is connected to the end of the output shaft of the motor 2. The bottom end of the agitator 3 extends to the bottom of the filter 4. The agitator 3 consists of a stirring rod and several stirring blades. The stirring blades are fixed to the bottom end of the stirring rod, and the top end of the stirring rod is fixed to the output shaft of the motor 2. The agitator 3 can ensure that the components in the wastewater are uniformly mixed, thereby improving the efficiency of subsequent treatment. In this process, pH adjusters, oxidants, or flocculants can be selectively added to pretreatment the wastewater for different types of antitumor drug wastewater.

[0033] High pressure pump 6, the inlet end of high pressure pump 6 is connected to a connecting pipe 5, the connecting pipe 5 is connected to the pretreatment component, the outlet end of high pressure pump 6 is connected to a connecting pipe 7, the high pressure pump 6 can press the pretreated wastewater into the connecting pipe 7.

[0034] The air pumping assembly includes an air compressor 9 and an air storage tank 10. The output end of the air compressor 9 is connected to the inside of the air storage tank 10. A connecting pipe 3 11 is connected to the air storage tank 10. The connecting pipe 3 11 is connected to the connecting pipe 2 7. It is worth mentioning that an accumulator 8 is provided on the connecting pipe 2 7. When the high-pressure pump 6 and the air compressor 9 are working, pressure fluctuations may occur. The accumulator 8 can absorb these fluctuations and ensure that the fluid entering the preheater 12 and the reactor 14 is kept at a stable high pressure.

[0035] Two reactors 14 are connected at their top ends, and one of the reactors 14 is connected to a connecting pipe 15 at its bottom end. The reaction principle in the reactor 14 is that under certain temperature (150~250℃) and pressure (1.1~8.0MPa), oxygen in the air reacts with water to generate hydroxyl radicals, which react with organic matter in the wastewater, thereby eliminating the special activity of the organic matter and achieving the purpose of treating antitumor drug wastewater. The reaction time of the mixture in the reactor 14 is 0.5-1h, which improves the inactivation speed compared with traditional treatment processes.

[0036] The cooler 16 has an inverted U-shaped cross-section. One end of the cooler 16 is connected to the connecting pipe 15, and the other end of the cooler 16 is connected to the connecting pipe 19. The highest point of the cooler 16 and the highest point of the connecting pipe 19 are on the same horizontal line, ensuring that any gas that may be generated can flow smoothly from the cooler 16 to the gas-liquid separator 20, preventing gas from accumulating at the high point of the pipe and forming gas resistance that affects the liquid flow. The interior of the side wall of the cooler 16 is hollow. The interior of the side wall of the cooler 16 is connected to the circulating water outlet pipe 17 and the circulating water inlet pipe 18, and the circulating water outlet pipe 17 and the circulating water inlet pipe 18 are located at the two ends of the cooler 16, respectively. The use of water circulation cooling can reduce processing costs and save resources.

[0037] The gas-liquid separator 20 is connected to the connecting pipe 19. The top of the gas-liquid separator 20 is connected to the exhaust pipe 22, and the bottom of the gas-liquid separator 20 is connected to the water outlet pipe 21 for discharging the oxidizing liquid.

[0038] It also includes a preheater 12, the bottom end of which is connected to the connecting pipe 2 7, and the top end of the preheater 12 is connected to the connecting pipe 4 13, which is connected to the bottom end of another reactor 14. Both the preheater 12 and the reactor 14 are fixedly fitted with heating jackets 23. The preheater 12 raises the temperature of the wastewater and air mixture to accelerate the reaction rate in the reactor 14.

[0039] Furthermore, the device is equipped with temperature transmitters, pressure transmitters, remote level gauges, and automatic control valves to monitor and control the pressure and temperature of various parts of the device. The gas-liquid separator 20 is equipped with high and low level alarm devices to improve safety performance. The control system for the device uses Siemens PLC-S7-1200 series, which has a human-machine interface, is easy to operate, and has expandable output, providing room for equipment upgrades.

[0040] The specific working principle of this utility model is as follows:

[0041] The wastewater from antitumor drugs is fed into the pretreatment tank 1. After passing through the filter 4 to remove internal solid particles, it is then stirred by the agitator 3 to ensure even distribution of the wastewater's components. Next, the high-pressure pump 6 and air compressor 9 are started. The high-pressure pump 6 pumps the pretreated wastewater from connecting pipe 1 (5) into connecting pipe 2 (7), while the air compressor 9 compresses air from the air storage tank 10 into connecting pipe 3 (11), which then mixes with the wastewater in connecting pipe 2 (7). The mixture enters the preheater 12 for initial heating and then enters the reactor 14 through connecting pipe 4 (13). Under specific temperature and pressure conditions, the wastewater is further treated. Oxygen in the air reacts with water to generate hydroxyl radicals, which react with organic matter in the wastewater, eliminating the special activity of the organic matter. The treated mixture then enters the cooler 16 through connecting pipe 5 15. Under the cooling effect of circulating water, the temperature drops to room temperature. The cooled mixture then enters the gas-liquid separator 20 through connecting pipe 6 19. Under the action of the gas-liquid separator 20, the gaseous part, including unreacted oxygen, nitrogen, and carbon dioxide that may be generated, is collected and safely discharged or further treated. The liquid part, containing oxidation products and other dissolved substances, is discharged as treated wastewater.

[0042] The above description is only a preferred embodiment of the present utility model, but the protection scope of the present utility model is not limited thereto. Any equivalent substitutions or changes made by those skilled in the art within the technical scope disclosed in the present utility model, based on the technical solution and the inventive concept of the present utility model, should be included within the protection scope of the present utility model.

Claims

1. An anti-tumor drug wastewater inactivation device, characterized by, include: Pretreatment components are used for the initial treatment of wastewater from antitumor drugs. A high-pressure pump (6) is provided with a connecting pipe (5) at its inlet end, which is connected to a pretreatment component. A connecting pipe (7) is provided at the outlet end of the high-pressure pump (6). The air pump assembly includes an air compressor (9) and an air tank (10). The output end of the air compressor (9) is connected to the inside of the air tank (10). A connecting pipe three (11) is connected to the air tank (10). The connecting pipe three (11) is connected to the connecting pipe two (7). Two reactors (14) are connected at their top ends, and one of the reactors (14) is connected to a connecting pipe (15) at its bottom end. A cooler (16) with an inverted U-shaped cross-section, one end of which is connected to a connecting pipe five (15), and the other end of which is connected to a connecting pipe six (19). A gas-liquid separator (20) is connected to a connecting pipe six (19). The top end of the gas-liquid separator (20) is connected to an exhaust pipe (22), and the bottom end of the gas-liquid separator (20) is connected to an outlet pipe (21) for discharging oxidizing liquid.

2. The anti-tumor pharmaceutical waste water inactivation apparatus according to claim 1, characterized by, The pretreatment assembly includes a pretreatment box (1), the bottom of the side wall of the pretreatment box (1) is connected to a connecting pipe (5), a filter (4) is provided in the upper part of the inner side of the pretreatment box (1), a motor (2) is fixed on the pretreatment box (1), and a stirrer (3) is shaft-connected to the end of the output shaft of the motor (2), and the bottom end of the stirrer (3) extends to the bottom of the filter (4).

3. The anti-tumor pharmaceutical waste water inactivation apparatus according to claim 1, characterized by, It also includes a preheater (12), the bottom end of which is connected to a connecting pipe two (7), and the top end of the preheater (12) is connected to a connecting pipe four (13), which is connected to the bottom end of another reactor (14).

4. The anti-tumor pharmaceutical waste water inactivation apparatus according to claim 3, characterized by, Heating jackets (23) are fixedly fitted on the outside of both the preheater (12) and the reactor (14).

5. The anti-tumor pharmaceutical waste water inactivation apparatus according to claim 1, characterized by, The interior of the side wall of the cooler (16) is hollow. The interior of the side wall of the cooler (16) is connected to a circulating water outlet pipe (17) and a circulating water inlet pipe (18), and the circulating water outlet pipe (17) and the circulating water inlet pipe (18) are located at the two ends of the cooler (16) respectively.

6. The antitumor drug waste water inactivation device according to claim 1, characterized by, The highest point of the cooler (16) is on the same horizontal line as the highest point of the connecting pipe six (19).

Images